JP2008156281A - CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME - Google Patents

CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME Download PDF

Info

Publication number
JP2008156281A
JP2008156281A JP2006347031A JP2006347031A JP2008156281A JP 2008156281 A JP2008156281 A JP 2008156281A JP 2006347031 A JP2006347031 A JP 2006347031A JP 2006347031 A JP2006347031 A JP 2006347031A JP 2008156281 A JP2008156281 A JP 2008156281A
Authority
JP
Japan
Prior art keywords
lipoic acid
lysine
crystals
ethanol
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006347031A
Other languages
Japanese (ja)
Inventor
Masahiko Shishido
雅彦 宍戸
Koichi Ueno
浩一 上野
Yuichi Nakagami
祐一 中神
Hiroki Moriwaki
浩樹 森脇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamari Chemicals Ltd
Original Assignee
Hamari Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamari Chemicals Ltd filed Critical Hamari Chemicals Ltd
Priority to JP2006347031A priority Critical patent/JP2008156281A/en
Publication of JP2008156281A publication Critical patent/JP2008156281A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a high purity crystalline salt of α-lipoic acid and L-lysine, and an industrial method for preparing the same. <P>SOLUTION: The industrial method for preparing a high purity crystalline salt of α-lipoic acid and L-lysine comprises gradually dripping an aqueous ethanol solution of L-lysine of a temperature of 0 to 10°C into an ethanol solution of α-lipoic acid of a temperature of 0 to 10°C, stirring the mixed solution at the same temperature as above, isolating precipitated crystals by a commonly known method, and drying the isolated crystals at a temperature of 40°C or lower under vacuum. Thus obtained salt of α-lipoic acid and L-lysine shows a melting temperature of 149 to 151°C and shows crystallinity by X-ray diffractometry. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は、α−リポ酸L−リジン塩の結晶およびその製造法に関する。   The present invention relates to crystals of α-lipoic acid L-lysine salt and a process for producing the same.

チオクト酸とも呼ばれるα−リポ酸(化学名1,2−ジチオラン−3−ペンタン酸)は、R(+)型として動物および植物細胞中に存在する天然物質である。このものは体内において糖代謝経路に含まれるケト酸の酸化的脱カルボキシル反応に必須な補酵素であり、また抗酸化作用を有することから、活性酸素の抑制による老化防止が期待されている。近年化学合成されたα−リポ酸が医薬品として、および食品サプリメントとして使用されている。   Α-Lipoic acid (chemical name 1,2-dithiolane-3-pentanoic acid), also called thioctic acid, is a natural substance present in animal and plant cells as the R (+) form. This is a coenzyme essential for the oxidative decarboxylation reaction of keto acid contained in the sugar metabolic pathway in the body, and since it has an antioxidant action, it is expected to prevent aging by suppressing active oxygen. Recently, α-lipoic acid chemically synthesized has been used as a medicine and a food supplement.

α−リポ酸は水に難溶なため、食品サプリメントには固体のα−リポ酸が使用されている。水溶性のα−リポ酸塩も知られている。これらのうち生理学的に意義がある有機塩基との塩として、FR4680Mにはα−リポ酸のリジン塩が記載されている。またEP318891にはα−リポ酸リジン塩を含む注射剤が記載されている。FR4680Mによると、α−リポ酸リジン塩は苦味のある融点153℃の白色粉末であり、中毒症候群および食欲欠乏障害の処置に有用であることが記載されている。製造方法の記載はないが、リジンもそのα−リポ酸塩も水によく溶けることから、リジンの水溶液へ理論量のα−リポ酸を添加し、生成した両者の塩の水溶液を濃縮乾固するか凍結乾燥して製造したものと推測される。本発明者らのこの方法の追試によって得た生成物が嵩高い無定形の白色粉末であったこともこれを裏付ける。   Since α-lipoic acid is hardly soluble in water, solid α-lipoic acid is used in food supplements. Water-soluble α-lipoic acid salts are also known. Among these, FR4680M describes a lysine salt of α-lipoic acid as a salt with a physiologically significant organic base. EP318891 describes an injection containing α-lipoic acid lysine salt. According to FR4680M, α-lipoic acid lysine salt is a white powder with a melting point of 153 ° C. having a bitter taste and is useful for the treatment of poisoning syndrome and anorexia disorder. Although there is no description of the production method, both lysine and its α-lipoic acid salt are well soluble in water. Therefore, a theoretical amount of α-lipoic acid is added to the lysine aqueous solution, and the resulting aqueous solution of both salts is concentrated to dryness It is presumed that it was manufactured by freeze drying. This is also supported by the fact that the product obtained by the inventors of this method was a bulky amorphous white powder.

しかしながらα−リポ酸リジン塩を結晶として提供することが望ましい。一般に晶析は均一な組成の高純度の製品を与えるからである。さらに結晶は無定形粉末よりも嵩密度および安息角が小さく、取扱い上便利である。   However, it is desirable to provide α-lipoic acid lysine salt as crystals. This is because crystallization generally gives a high purity product with a uniform composition. Furthermore, the crystal has a smaller bulk density and angle of repose than the amorphous powder, which is convenient for handling.

本発明は、結晶性α−リポ酸リジン塩と、晶析法によって結晶性のα−リポ酸リジン塩を製造する方法を提供する。   The present invention provides a crystalline α-lipoic acid lysine salt and a method for producing a crystalline α-lipoic acid lysine salt by a crystallization method.

スペイン特許第313056号は、水系で当量のα−リポ酸とDL−リジン塩を反応させ、融点160〜164℃のα−リポ酸DL−リジン塩を得たことを記載している。   Spanish Patent No. 313056 describes that an α-lipoic acid DL-lysine salt having a melting point of 160 to 164 ° C. was obtained by reacting an equivalent amount of α-lipoic acid with a DL-lysine salt in an aqueous system.

ところがリジン塩基は水に殆ど自由に溶けるのに対し、α−リポ酸は水に難溶であるから、リジン水溶液へ理論量のα−リポ酸を加えて両者の塩を水溶液として生成させ、これを減圧濃縮するか凍結乾燥して粉末として回収するほかはなかった。   However, while lysine base is almost freely soluble in water, α-lipoic acid is hardly soluble in water, so the theoretical amount of α-lipoic acid is added to an aqueous lysine solution to form both salts as an aqueous solution. There was no other choice than to concentrate the product under reduced pressure or freeze-dry it and collect it as a powder.

しかしながらα−リポ酸リジン塩を反応液から晶析により結晶として分離することが望ましい。一般に晶析は高純度の製品を与え、さらに結晶は無定形粉末よりも嵩密度および安息角が小さく、取扱い上便利であるからである。   However, it is desirable to separate the α-lipoic acid lysine salt from the reaction solution as a crystal by crystallization. This is because crystallization generally gives a high-purity product, and crystals have a smaller bulk density and angle of repose than amorphous powders, which is convenient for handling.

α−リポ酸は水に難溶であるがエタノールには可溶である。反対にL−リジン(塩基)は水に殆ど自由に溶けるがエタノールを含む通常の有機溶媒には難溶である。本発明はこの性質を利用し、それぞれ理論量のα―リポ酸はエタノールに溶解し、L−リジンは一旦水溶液とした後これへエタノールを加えてL−リジンの含水エタノール溶液を生成させ、このように調製したL−リジンの含水エタノール溶液をα―リポ酸のエタノール溶液へ徐々に滴下し、攪拌することによって両者の塩を結晶として析出させる。その後析出した結晶を母液から常法によって分離し、エタノールで洗浄した後、40℃以下の温度で減圧乾燥することによってα−リポ酸L−リジン塩の結晶を製造する。その際すべての液体、すなわちα−リポ酸のエタノール溶液、L−リジンの含水エタノール溶液、結晶がそれから析出する母液、および結晶を洗浄するエタノールの温度は0℃ないし10℃に保つことが重要である。これは晶出時の塩の過飽和溶解度を下げるためと、α−リポ酸が重合した不純物の混入を避けるためである。   α-Lipoic acid is hardly soluble in water but soluble in ethanol. On the contrary, L-lysine (base) is almost freely soluble in water, but hardly soluble in ordinary organic solvents including ethanol. The present invention utilizes this property, and each theoretical amount of α-lipoic acid is dissolved in ethanol, L-lysine is once made into an aqueous solution, and ethanol is added thereto to produce a hydrous ethanol solution of L-lysine. The aqueous ethanol solution of L-lysine prepared as described above is gradually added dropwise to the ethanol solution of α-lipoic acid and stirred to precipitate both salts as crystals. Thereafter, the precipitated crystals are separated from the mother liquor by a conventional method, washed with ethanol, and dried under reduced pressure at a temperature of 40 ° C. or lower to produce α-lipoic acid L-lysine salt crystals. At that time, it is important to keep the temperature of all liquids, that is, ethanol solution of α-lipoic acid, aqueous ethanol solution of L-lysine, mother liquor from which crystals are precipitated, and ethanol for washing the crystals at 0 ° C. to 10 ° C. is there. This is to reduce the supersaturated solubility of the salt at the time of crystallization and to avoid the contamination of α-lipoic acid polymerized impurities.

このようにして得られるα−リポ酸L−リジン塩結晶は融点149〜151℃を示し、これまで報告されたこのものの融点と異なり、不純物の混入が極めて少ないことを示している。さらに結晶はX線回折において明らかに結晶であることを示す。さらにこの方法に使用する溶媒は生理的に無害な水およびエタノールのみであり、このことは食品サプリメントとしての用途において必須である。   The α-lipoic acid L-lysine salt crystal thus obtained has a melting point of 149 to 151 ° C., which is different from the melting point of the one reported so far, indicating that there is very little contamination with impurities. Furthermore, the crystal is clearly crystallized by X-ray diffraction. Furthermore, the only solvents used in this method are physiologically harmless water and ethanol, which is essential for use as a food supplement.

本発明によるα−リポ酸L−リジン塩結晶の製造法を工程別に記載すると、
(a)α−リポ酸を所要量のエタノールに溶解する工程;
(b)α−リポ酸に対し理論量のL−リジンを水に溶解し、この水溶液へエタノールを添加してL−リジンの含水エタノールを生成させる工程;
(c)工程(a)で得たα−リポ酸溶液へ工程(b)で得たL−リジン溶液を徐々に滴下し、攪拌して結晶を析出させる工程;
(d)工程(c)で析出した結晶を常法(例えば遠心分離)により母液から分離し、エタノールで洗浄する工程;
(e)分離した結晶を40℃以下の温度で減圧乾燥する工程よりなり、
(f)工程(a)ないし(d)は液温0〜10℃において実施される。
The production method of α-lipoic acid L-lysine salt crystals according to the present invention will be described according to the process.
(A) dissolving α-lipoic acid in a required amount of ethanol;
(B) A step of dissolving a theoretical amount of L-lysine in α-lipoic acid in water and adding ethanol to the aqueous solution to produce L-lysine hydrous ethanol;
(C) The step of gradually dropping the L-lysine solution obtained in step (b) into the α-lipoic acid solution obtained in step (a) and stirring to precipitate crystals;
(D) a step of separating the crystals precipitated in step (c) from the mother liquor by a conventional method (for example, centrifugation) and washing with ethanol;
(E) comprising a step of drying the separated crystals under reduced pressure at a temperature of 40 ° C. or lower,
(F) Steps (a) to (d) are performed at a liquid temperature of 0 to 10 ° C.

この際工程(d)において洗浄に使用するエタノールを除いて、それ以前に使用するエタノールおよび水の量はできるだけ少ない方が効率的であり、かつ結晶の最終収率も高い。しかしながら工程(c)において結晶が析出する母液(含水エタノール)は、生成した塩の大部分が結晶として析出するように塩で過飽和状態にあることが必要である。そのためL−リジンを溶解するための水の量は、リジン水溶液へ添加されるアルコールおよび最初にα−リポ酸を溶解するためのアルコールの合計量に対して容積比で10/90ないし3/97の範囲にあることが好ましい。換言すると、(c)工程において結晶はエタノール濃度90v/v%以上の含水エタノールから析出させるのが好ましい。例えばα−リポ酸を40〜48L/kgのエタノールに溶解し、一方当量のリジン−水和物を1.8〜2.2L/kgの水に溶解した後2〜10L/kgのエタノールを添加し、これをα−リポ酸のアルコール溶液へ滴下する。これによりエタノールおよび全体の液量が少なくてすみ、かつ塩の結晶収率も例えば80〜90%に向上するので工業的生産に適している。   At this time, except for ethanol used for washing in step (d), it is more efficient to use as little ethanol and water as possible before that, and the final yield of crystals is also high. However, the mother liquor (hydrated ethanol) from which crystals are precipitated in step (c) needs to be supersaturated with salt so that most of the produced salt precipitates as crystals. Therefore, the amount of water for dissolving L-lysine is 10/90 to 3/97 by volume with respect to the total amount of alcohol added to the lysine aqueous solution and alcohol for initially dissolving α-lipoic acid. It is preferable that it exists in the range. In other words, in the step (c), the crystal is preferably precipitated from hydrous ethanol having an ethanol concentration of 90 v / v% or more. For example, α-lipoic acid is dissolved in 40 to 48 L / kg of ethanol, while equivalent lysine hydrate is dissolved in 1.8 to 2.2 L / kg of water and then 2 to 10 L / kg of ethanol is added. Then, this is dropped into an alcohol solution of α-lipoic acid. As a result, the amount of ethanol and the whole liquid can be reduced, and the crystal yield of the salt is improved to, for example, 80 to 90%, which is suitable for industrial production.

原料α−リポ酸は通常ラセミ体であるが、これを光学分割して得られるR(+)型異性体を使用することもできる。L−リジン(遊離塩基)は一水和物として市場で入手することが可能であるからこれを使用するのが便利である。   The raw material α-lipoic acid is usually a racemate, but R (+) type isomers obtained by optical resolution can also be used. L-lysine (free base) is convenient to use because it is commercially available as a monohydrate.

以下に限定を意図しない実施例を挙げて本発明を例証する。   The invention is illustrated by the following non-limiting examples.

予め内部を洗浄、乾燥した反応容器へエタノール800Lを仕込み、内温0〜10℃に冷却し、これにα−リポ酸20.0kg(96.9mol,1当量)を加えて溶解する。予め洗浄、乾燥した同様な反応容器へ精製水(日局)40LとL−リジン−水和物15.9kg(96.9mol,1当量)を仕込み、溶解する。これにエタノール120Lを添加し、内温0〜10℃に冷却する。   800 L of ethanol is charged into a reaction vessel whose interior has been washed and dried in advance, and cooled to an internal temperature of 0 to 10 ° C., and 20.0 kg (96.9 mol, 1 equivalent) of α-lipoic acid is added and dissolved therein. In a similar reaction vessel washed and dried in advance, 40 L of purified water (JP) and 15.9 kg (96.9 mol, 1 equivalent) of L-lysine-hydrate are charged and dissolved. 120 L of ethanol is added to this, and it cools to internal temperature 0-10 degreeC.

内温を0〜10℃に保ちながら、α−リポ酸溶液へL−リジン溶液を20〜60分を要して滴下し、さらに同温度で1時間以上攪拌する。内温0〜10℃に保ちながら析出した結晶を含むスラリーを遠心分離機にかけ、分離した結晶を0〜10℃に保ったエタノール40Lで洗浄する。洗浄した湿晶を真空乾燥機に移し、40℃以下(温水設定温度40℃)で乾燥減量が5%以下になるまで乾燥する。α−リポ酸L−リジン塩の結晶27.4〜30.8kgが得られる。収率80〜90%   While maintaining the internal temperature at 0 to 10 ° C., the L-lysine solution is dropped into the α-lipoic acid solution over 20 to 60 minutes, and further stirred at the same temperature for 1 hour or more. While maintaining the internal temperature at 0 to 10 ° C., the slurry containing the precipitated crystals is centrifuged, and the separated crystals are washed with 40 L of ethanol maintained at 0 to 10 ° C. The washed wet crystals are transferred to a vacuum dryer and dried at 40 ° C. or lower (warm water set temperature 40 ° C.) until the loss on drying is 5% or lower. 27.4-30.8 kg of crystals of α-lipoic acid L-lysine salt are obtained. Yield 80-90%

得られた結晶は149〜151℃の融点を示し、図1のX線解析チャートに示すとおり、明確に結晶であることを示した。   The obtained crystal had a melting point of 149 to 151 ° C., and was clearly a crystal as shown in the X-ray analysis chart of FIG.

本発明のα−リポ酸L−リジン塩のX線回折チャートである。2 is an X-ray diffraction chart of α-lipoic acid L-lysine salt of the present invention.

Claims (4)

液温0〜10℃のα−リポ酸エタノール溶液へ液温0〜10℃のL−リジン含水エタノール溶液を徐々に滴下し、さらに同温度において混合液を攪拌することによって析出した結晶を母液から分離し、40℃以下の温度で減圧乾燥することを特徴とするα−リポ酸L−リジン塩結晶の製造法。   An L-lysine hydrous ethanol solution having a liquid temperature of 0 to 10 ° C. is gradually added dropwise to an α-lipoic acid ethanol solution having a liquid temperature of 0 to 10 ° C., and the mixed solution is stirred at the same temperature, whereby crystals precipitated from the mother liquor are removed. A method for producing α-lipoic acid L-lysine salt crystals, which is separated and dried under reduced pressure at a temperature of 40 ° C. or lower. 母液から分離した結晶を減圧乾燥する前に、0〜10℃の冷エタノールで洗浄する工程を含む請求項1の方法。   The method according to claim 1, further comprising the step of washing with 0 to 10 ° C cold ethanol before drying the crystals separated from the mother liquor under reduced pressure. (a)α−リポ酸を所要量のエタノールに溶解する工程;
(b)α−リポ酸へ対して理論量のL−リジンを含水エタノールに溶解する工程;
(c)工程(a)で得たα−リポ酸溶液へ工程(b)で得たL−リジン溶液を徐々に滴下し、攪拌して結晶を析出させる工程;
(d)工程(c)で析出させた結晶を常法により母液から分離し、エタノールで洗浄する工程;
(e)分離した結晶を40℃以下の温度で減圧乾燥する工程;よりなり、
(f)工程(a)ないし(d)は液温0〜10℃において実施され;
(g)工程(a)および(b)において使用するアルコールおよび水の量は工程(c)において結晶が析出する母液のエタノール濃度が90v/v%以上となる量である;
ことを特徴とするα−リポ酸L−リジン塩結晶の製造法。
(A) a step of dissolving α-lipoic acid in a required amount of ethanol;
(B) a step of dissolving a theoretical amount of L-lysine in α-lipoic acid in hydrous ethanol;
(C) The step of gradually dropping the L-lysine solution obtained in step (b) into the α-lipoic acid solution obtained in step (a) and stirring to precipitate crystals;
(D) a step of separating the crystals precipitated in step (c) from the mother liquor by a conventional method and washing with ethanol;
(E) a step of drying the separated crystals under reduced pressure at a temperature of 40 ° C. or lower;
(F) Steps (a) to (d) are performed at a liquid temperature of 0 to 10 ° C;
(G) The amount of alcohol and water used in steps (a) and (b) is such that the ethanol concentration of the mother liquor in which crystals precipitate in step (c) is 90 v / v% or higher;
A process for producing an α-lipoic acid L-lysine salt crystal characterized by the above.
融点149〜151℃を示すα−リポ酸L−リジン塩結晶。   Α-Lipoic acid L-lysine salt crystals having a melting point of 149 to 151 ° C.
JP2006347031A 2006-12-25 2006-12-25 CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME Pending JP2008156281A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006347031A JP2008156281A (en) 2006-12-25 2006-12-25 CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006347031A JP2008156281A (en) 2006-12-25 2006-12-25 CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME

Publications (1)

Publication Number Publication Date
JP2008156281A true JP2008156281A (en) 2008-07-10

Family

ID=39657615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006347031A Pending JP2008156281A (en) 2006-12-25 2006-12-25 CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME

Country Status (1)

Country Link
JP (1) JP2008156281A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001195A (en) * 2015-07-06 2015-10-28 南京海融医药科技有限公司 New crystal form of R(+)-thioctic acid-L-lysinate and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001195A (en) * 2015-07-06 2015-10-28 南京海融医药科技有限公司 New crystal form of R(+)-thioctic acid-L-lysinate and preparation method thereof

Similar Documents

Publication Publication Date Title
KR101844605B1 (en) L-ornithine phenyl acetate and methods of making thereof
JP6160621B2 (en) Pyrroloquinoline quinone tetraalkali salt and crystal thereof, production method thereof, and composition
CA2779539A1 (en) Pyrroloquinoline quinone in free form
KR20170105522A (en) Crystals of ammonium salt of N-acetylnoiramic acid anhydride and method for producing the same
KR101899015B1 (en) Process for the production of l-carnitine tartrate
CN104185621B (en) For the method preparing 3-mesyl propionitrile
JP2008156281A (en) CRYSTALLINE SALT OF alpha-LIPOIC ACID AND L-LYSINE, AND METHOD FOR PREPARING THE SAME
JP2006265202A (en) Alpha-lipoic acid amino acid salt
CN110114333B (en) Improved synthesis of lysine acetylsalicylate glycine particles
FR2752423A1 (en) Stable, therapeutically active glucosamine sulphate preparation
WO2017222043A1 (en) Crystal of β-hydroxy β-methylbutyric acid amino acid salt and production method therefor
ITMI20060422A1 (en) DIRECT PROCEDURE FOR THE PRODUCTION OF DICHLORIDRATE OF AN AMINO ACID
JP4902940B2 (en) Salt of acetyl L-carnitine with dicarboxyl organic acid and process for its preparation
CN106187927B (en) Preparation method of Lesinurad intermediate
JP2008156282A (en) SALT OF alpha-LIPOIC ACID AND L-ORNITHINE, AND METHOD FOR PREPARING THE SAME
JP2021080284A (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and process for producing the crystals
CN106187799B (en) A method of preparing DL-lysine hydrochloride
JPS60120886A (en) Crystal of cephemcarboxylic acid sodium salt
JP2007070238A (en) MANUFACTURING METHOD OF CRYSTALLINE alpha-LIPOATE SALT
TWI768595B (en) An efficient crystallization process for preparing ultrapure treprostinil and crystal prepared therefrom
JP3931884B2 (en) Tablet manufacturing method
WO2017195743A1 (en) Crystal of 3&#39;-sialyllactose sodium salt n-hydrate, and method for producing same
JP2022534087A (en) Novel crystalline form of treprostinil sodium and method of preparation
JP2022535927A (en) Improved methods for synthesizing and purifying citrulline
JP3900302B2 (en) Method for producing crystalline calcium calcium aspartate